The SERENITY At-Home Phase 3 trial is a double-blind, placebo-controlled study designed to evaluate the safety of a 120 mcg dose of BXCL501 for the acute treatment of agitation associated with bipolar ...

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...

Net Loss: BioXcel Therapeutics an operating loss of $15.9 million and a net loss of $19.2 million for the second quarter of 2025, compared to an operating loss of $17.3 million and net loss of $8.3 ...

“ With Global Blood Therapeutics’ talent, portfolio, and pipeline now part of Pfizer, we look forward to accelerating innovation and expeditiously bringing multiple potential best-in-class ...

Benzinga Pro data, Global Blood Therapeutics (NASDAQ:GBT) reported Q2 sales of $71.55 million. Earnings fell to a loss of $82.47 million, resulting in a 1.29% decrease from last quarter.

Pfizer has reached an agreement to acquire Global Blood Therapeutics in a deal worth over $5 billion.

Pfizer has acquired sickle cell disease specialist Global Blood Therapeutics for $5.4 billion. Analysts say the deal helps Pfizer diversify its business and recharge its growth. Live on Wednesday ...

Pfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic. Pfizer said ...

The New York drugmaker is buying Global Blood Therapeutics, which sells a drug for sickle-cell disease and has two in development. It will pay $68.50 per share.